Clinical trials
Glioblastoma clinical trials
Below are recruiting glioblastoma clinical trials, each written for real people, not researchers. We’re tracking 317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07193654RecruitingPhase 2
Combined stupp therapy and spinal chemo for advanced glioblastoma
This trial tests adding a chemotherapy drug (thiotepa) directly into the spinal fluid for people with a newly diagnosed glioblastoma that has spread to the brain's lining or ventricles. It aims to see if this extra treatment can help control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07263438RecruitingPhase 2
Trimipramine, atezolizumab, and bevacizumab for recurrent glioblastoma
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Basel, BaselAges 18 years+ - NCT07274397Recruiting
Early brain scan study after glioblastoma surgery
This study tests whether it is safe and possible to do a special brain scan (nuclear imaging) within the first 3 days after surgery for glioblastoma. It may help doctors understand how well the tumor was removed and guide future treatments.
CréteilAges 18 years+ - NCT07284069RecruitingEarly Phase 1
Senicapoc and perampanel for newly diagnosed glioblastoma
This trial tests two drugs, senicapoc and perampanel, added to standard treatment for people with newly diagnosed glioblastoma. The goal is to see if they can help slow tumor growth or improve outcomes.
Aarhus, DenmarkAges 18 years+ - NCT07297212RecruitingPhase 2
Testing the drug pumitamig for recurrent glioblastoma
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
BeijingAges 18–75 - NCT07343986RecruitingPhase 1
Ultrasound and Immunotherapy for Newly Diagnosed Brain Cancer
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
Charlottesville, VirginiaAges 18–70 - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Gilbert, ArizonaAges 18 years+ - NCT07364786RecruitingPhase 2
Testing Salovum for glioblastoma: oxygen and pressure
This trial tests if Salovum, a special egg yolk product, can improve oxygen levels and reduce pressure and inflammation in the brain for people with a suspected glioblastoma. It involves a biopsy before treatment starts.
LundAges 18–75 - NCT07375992Recruiting
Music therapy for newly diagnosed glioblastoma
This trial tests whether attending virtual music therapy sessions can help people with newly diagnosed glioblastoma feel better after chemoradiation. It aims to improve quality of life and emotional well-being.
Baltimore, MarylandAges 18 years+ - NCT07387666RecruitingEarly Phase 1
Imaging a common drug in glioblastoma
This trial uses a special imaging technique to see how the drug Acetadote (often used for acetaminophen overdose) behaves in glioblastoma tumors. It may help doctors learn more about the tumor and could guide future treatments.
Dallas, TexasAges 18 years+ - NCT07392957RecruitingPhase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
St Louis, MissouriAges 18 years+ - NCT00083512Recruiting
Blood and Urine Collection in Glioblastoma Radiation Therapy
This study collects blood and urine samples from patients receiving radiation treatment for glioblastoma (a serious brain tumor) to help researchers understand how the body responds to radiation therapy. Participating is straightforward—you provide samples during your regular treatment.
Bethesda, MarylandAges 18–120 - NCT02394626RecruitingPhase 2
Surgery for glioblastoma that has come back
This trial studies whether operating on a brain tumor that has returned can help people with recurrent glioblastoma. It focuses on people whose scans suggest surgery is safe for important speech and movement brain areas.
InnsbruckAges 18 years+ - NCT02861898RecruitingPhase 1/Phase 2
Cetuximab delivered into the brain tumor artery for new glioblastoma
This Phase 1/2 study tests whether giving cetuximab directly into the artery that feeds the brain tumor can help people with newly diagnosed glioblastoma. It aims to target the tumor more precisely while checking safety and early signs of benefit.
New York, New YorkAges 18 years+ - NCT07409584Recruiting
Mental health and suicide risk in glioblastoma patients
This study looks at the mental health and thoughts of suicide in people with glioblastoma. It aims to understand these issues better so that patients can get the right support.
BerlinAges 18 years+ - NCT07461948RecruitingPhase 3
Advanced imaging study for glioblastoma patients
This trial uses special MRI scans and a contrast agent to look at the immune environment of glioblastoma tumors. It may help doctors learn more about how the tumor responds to treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07464925RecruitingPhase 1
Testing GLIX1 for adults with returning high-grade glioma
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
Tampa, FloridaAges 18 years+ - NCT07485049RecruitingEarly Phase 1
BGB-58067 for newly diagnosed glioblastoma with MTAP deletion
This early-stage trial tests an experimental drug (BGB-58067) for people with a newly diagnosed glioblastoma that has a specific gene deletion (MTAP). It aims to see if the drug can shrink the tumor or slow its growth.
Phoenix, ArizonaAges 18 years+ - NCT07284628RecruitingPhase 2
Vortioxetine for newly diagnosed glioblastoma
This trial tests whether the antidepressant vortioxetine can help people with newly diagnosed glioblastoma when added to standard radiation and chemotherapy. The goal is to see if it improves mood, quality of life, and possibly treatment outcomes.
ZurichAges 18 years+ - NCT07488754Recruiting
Targeted radiation therapy for new glioma (grade 3-4)
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
Warsaw, PolandAges 18–80 - NCT07511725RecruitingPhase 2
Thiotepa spinal injection to prevent glioblastoma spread
This trial tests whether injecting a chemotherapy drug called thiotepa into the fluid around the brain and spine can prevent glioblastoma from spreading in patients whose tumor touches the fluid-filled spaces or who had a leak during surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07538128RecruitingEarly Phase 1
New drug YSCH-01 with immunotherapy for recurrent brain cancer
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT07552233Recruiting
NK Cell Therapy for Recurrent Brain Tumors
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma?
- Yes. Clin2 currently lists 317 recruiting glioblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.